Terns Pharmaceuticals Inc (TERN) 뉴스

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in...

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”...

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety...

Form 8-K - Current report

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

FOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”...

Form 8-K - Current report

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”...

Form 8-K - Current report

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

FOSTER CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities